ArchCath recognized as finalist InnoVision awards

Read more
Contact us

Investors

Advanced solutions

Revolutionary product

Invest in the future of
cardiac care

Join us in transforming cardiac procedures with innovative technology designed for safety and efficiency.

About us
GateKeeper

Investment opportunity

Invest in the future with ArchCath

ArchCath stands at the forefront of the MedTech industry with our revolutionary GateKeeper® Catheter, designed to significantly reduce stroke risks associated with TAVR procedures. With an increasing global demand for advanced cardiac care solutions and a strong pipeline of patent-protected products, ArchCath presents a unique investment opportunity. Invest in technology that’s not only leading innovation but also creating substantial market impact.

"The global transcatheter heart valve replacement (TAVR) market is worth US$ 5.7 Billion for 2022, and is set to expand 4.0X over the next ten years."

Why Invest?

The GateKeeper® Catheter market potential

Expanding global market

The global TAVR market is projected to reach USD 8 billion by 2025, driven by an aging population and increasing preference for minimally invasive surgeries.

Increasing demand

Stroke is a major risk of TAVR procedures. Innovations like the GateKeeper® Catheter that effectively reduce this risk meet a critical and growing demand in cardiac care.

Technological advancement

Continuous advancements in medical technology fuel the need for devices like the GateKeeper® Catheter that offer safer and more efficient outcomes.

Regulatory support

Regulatory bodies are increasingly supportive of technologies that improve patient outcomes. The FDA’s 510(k) clearance of the GateKeeper® demonstrates its recognized potential.

Regulatory support

Regulatory bodies are increasingly supportive of technologies that improve patient outcomes. The FDA’s 510(k) clearance of the GateKeeper® demonstrates its recognized potential.

Insurance and reimbursement

Expanding insurance coverage for TAVR procedures and associated protective technologies ensures broader market accessibility and adoption.

Long-term cost savings

Reducing complications such as strokes in TAVR procedures can lead to significant long-term cost savings for healthcare systems worldwide.

Scalability potential

The scalable nature of the GateKeeper® Catheter’s production can meet increasing global demands efficiently, supporting rapid market penetration and growth.

Connect with our team

For more detailed information and to discuss potential investment opportunities, please contact our Investor Relations team. We are ready to support you in making an informed investment decision and welcome you to the ArchCath family.

Get in touch now

For Investors

Investing in GateKeeper® Catheter

The GateKeeper® Catheter represents a significant advancement in MedTech, offering substantial growth potential. Invest in a technology
that’s set to redefine standarts in cardiac care and stroke prevention.

Market Pontential

Capitalize on the expanding market for
TAVR procedures and stroke prevention technologies

Innovation and Growth

Be part of pioneering journey with a product backed by robust patents and proven market demand

Market Pontential

Capitalize on the expanding market for
TAVR procedures and stroke prevention technologies

Innovation and Growth

Be part of pioneering journey with a product backed by robust patents and proven market demand

Timeline

Milestones and achievements

2016

Company formation and first US patent issuance.

2019

Successful prototype development and proof-of-concept animal trials.

2021

FDA 510(k) clearance received, enabling clinical application.

2021

First-in-human testing demonstrated safety and efficacy.

2022 - 2024

Ongoing clinical studies and preparation for pivotal trials.

Learn more about GateKeeper